Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study-Reference-Cited by-同舟云学术

Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study

Published:2017-11 Issue: Volume:62 Page:77-83
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Visani Giuseppe,Ferrara Felicetto,Di Raimondo Francesco,Loscocco Federica,Fuligni Fabio,Paolini Stefania,Zammit Valentina,Spina Eleonora,Rocchi Marco,Visani Axel,Piccaluga Pier Paolo,Isidori Alessandro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Cancer statistics, 2013;Siegel;CA. Cancer J. Clin.,2013

2. Progress in the treatment of acute myeloid leukemia;Ravandi;Cancer,2007

3. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia;Kantarjian;Blood,2010

4. Acute myeloid leukemia and myelodysplastic syndromes in older patients;Estey;J. Clin. Oncol.,2007

5. Going beyond 7+3 regimens in the treatment of adult acute myeloid leukemia;Tefferi;J. Clin. Oncol.,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of fresh soy milk and its compounds on apoptosis in human leukemic cells and peripheral blood mononuclear cells;Tropical Journal of Pharmaceutical Research;2022-01-17

2. Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?;Haematologica;2021-07-29

3. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial;Blood Advances;2021-02-22

4. Tumour vasculature: Friend or foe of oncolytic viruses?;Cytokine & Growth Factor Reviews;2020-12

5. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?;Expert Review of Hematology;2020-09-17